Cargando…
The pharmacokinetics of levobupivacaine 0.5% after infraorbital or inferior alveolar block in anesthetized dogs
INTRODUCTION: Data are lacking on the pharmacokinetic profile and safety of levobupivacaine (LB) used for regional anesthesia of the maxilla and mandibles in dogs. METHODS: Infraorbital block (n = 10), inferior alveolar block (n = 10) or both infraorbital and inferior alveolar blocks (n = 10) were a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794753/ https://www.ncbi.nlm.nih.gov/pubmed/36590797 http://dx.doi.org/10.3389/fvets.2022.1055231 |
_version_ | 1784860100060512256 |
---|---|
author | Pavlica, Matic Kržan, Mojca Nemec, Ana Kosjek, Tina Baš, Anže Seliškar, Alenka |
author_facet | Pavlica, Matic Kržan, Mojca Nemec, Ana Kosjek, Tina Baš, Anže Seliškar, Alenka |
author_sort | Pavlica, Matic |
collection | PubMed |
description | INTRODUCTION: Data are lacking on the pharmacokinetic profile and safety of levobupivacaine (LB) used for regional anesthesia of the maxilla and mandibles in dogs. METHODS: Infraorbital block (n = 10), inferior alveolar block (n = 10) or both infraorbital and inferior alveolar blocks (n = 10) were administered to dogs undergoing dental surgery under isoflurane anesthesia. The dose of LB was calculated as 0.11 ml/kg(2/3) for the infraorbital block and 0.18 ml/kg(2/3) for the inferior alveolar block. Blood samples were collected before and immediately after administration of the oral blocks, and 3, 4, 7, 12, 17, 32, 47, 62, 92, and 122 min thereafter. Quantification of LB in plasma was performed by LC-MS/MS. RESULTS AND DISCUSSION: The results are presented as median and interquartile range. In dogs in which all four quadrants of the oral cavity were desensitized with LB, the C(max) was 1,335 (1,030–1,929) ng/ml, the T(max) was 7 (4–9.5) min, and the AUC((0 → 120)) was 57,976 (44,954–96,224) ng min/ml. Plasma concentrations of LB were several times lower than the reported toxic concentrations, and no signs of cardiovascular depression or neurotoxicity were observed in any of the dogs, suggesting that the occurrence of severe adverse effects after administration of LB at the doses used in this study is unlikely. |
format | Online Article Text |
id | pubmed-9794753 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97947532022-12-29 The pharmacokinetics of levobupivacaine 0.5% after infraorbital or inferior alveolar block in anesthetized dogs Pavlica, Matic Kržan, Mojca Nemec, Ana Kosjek, Tina Baš, Anže Seliškar, Alenka Front Vet Sci Veterinary Science INTRODUCTION: Data are lacking on the pharmacokinetic profile and safety of levobupivacaine (LB) used for regional anesthesia of the maxilla and mandibles in dogs. METHODS: Infraorbital block (n = 10), inferior alveolar block (n = 10) or both infraorbital and inferior alveolar blocks (n = 10) were administered to dogs undergoing dental surgery under isoflurane anesthesia. The dose of LB was calculated as 0.11 ml/kg(2/3) for the infraorbital block and 0.18 ml/kg(2/3) for the inferior alveolar block. Blood samples were collected before and immediately after administration of the oral blocks, and 3, 4, 7, 12, 17, 32, 47, 62, 92, and 122 min thereafter. Quantification of LB in plasma was performed by LC-MS/MS. RESULTS AND DISCUSSION: The results are presented as median and interquartile range. In dogs in which all four quadrants of the oral cavity were desensitized with LB, the C(max) was 1,335 (1,030–1,929) ng/ml, the T(max) was 7 (4–9.5) min, and the AUC((0 → 120)) was 57,976 (44,954–96,224) ng min/ml. Plasma concentrations of LB were several times lower than the reported toxic concentrations, and no signs of cardiovascular depression or neurotoxicity were observed in any of the dogs, suggesting that the occurrence of severe adverse effects after administration of LB at the doses used in this study is unlikely. Frontiers Media S.A. 2022-12-14 /pmc/articles/PMC9794753/ /pubmed/36590797 http://dx.doi.org/10.3389/fvets.2022.1055231 Text en Copyright © 2022 Pavlica, Kržan, Nemec, Kosjek, Baš and Seliškar. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Veterinary Science Pavlica, Matic Kržan, Mojca Nemec, Ana Kosjek, Tina Baš, Anže Seliškar, Alenka The pharmacokinetics of levobupivacaine 0.5% after infraorbital or inferior alveolar block in anesthetized dogs |
title | The pharmacokinetics of levobupivacaine 0.5% after infraorbital or inferior alveolar block in anesthetized dogs |
title_full | The pharmacokinetics of levobupivacaine 0.5% after infraorbital or inferior alveolar block in anesthetized dogs |
title_fullStr | The pharmacokinetics of levobupivacaine 0.5% after infraorbital or inferior alveolar block in anesthetized dogs |
title_full_unstemmed | The pharmacokinetics of levobupivacaine 0.5% after infraorbital or inferior alveolar block in anesthetized dogs |
title_short | The pharmacokinetics of levobupivacaine 0.5% after infraorbital or inferior alveolar block in anesthetized dogs |
title_sort | pharmacokinetics of levobupivacaine 0.5% after infraorbital or inferior alveolar block in anesthetized dogs |
topic | Veterinary Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794753/ https://www.ncbi.nlm.nih.gov/pubmed/36590797 http://dx.doi.org/10.3389/fvets.2022.1055231 |
work_keys_str_mv | AT pavlicamatic thepharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs AT krzanmojca thepharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs AT nemecana thepharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs AT kosjektina thepharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs AT basanze thepharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs AT seliskaralenka thepharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs AT pavlicamatic pharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs AT krzanmojca pharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs AT nemecana pharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs AT kosjektina pharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs AT basanze pharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs AT seliskaralenka pharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs |